Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracoronary Alprostadil vs Nicorandil in STEMI
NCT03252665Phase 4Unknown
- Sponsor
- Renji Hospital
- Start
- Sep 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Vasostenoon and nicorandil in ST-segment elevation myocardial infarction (STEMI) (3 arms), sponsored by Renji Hospital. Primary endpoints: TIMI Myocardial Perfusion Frame Count and TIMI Myocardial Perfusion Grade. Status: unknown.
02
Drugs
Vasostenoonnicorandil
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT03252665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03252665.